Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
Acadia Pharmaceuticals Presents DAYBUE Real-World Evidence And Additional Data In Rett Syndrome At The 2024 IRSF Annual Scientific Meeting
阿卡迪亞製藥在2024年IRSF年會上展示霞症的DAYBUE實際證據和其他數據
Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD) today announced that interim data from the open-label real-world LOTUS study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE (trofinetide).
Acadia Pharmaceuticals公司（納斯達克股票代碼：ACAD）今天宣佈，開放標籤真實世界LOTUS研究的中期數據將在本週舉行的2024年國際Rett綜合徵基金會（IRSF）年度科學會議上展示，地點在科羅拉多州威斯敏斯特市。LOTUS是一項正在進行中、以護理者報告爲基礎，評估Rett綜合徵患者使用DAYBUE（trofinetide）治療的有效性和耐受性結果的研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。